[Cerebrovascular manifestations while taking combined estrogens and progestins for contraceptive purposes. Clinical cases].
This study concerns 20 patients with cerebrovascular disease in the course of oral contraception with estrogens/progestins. The assumption of oral contraceptives appears to be related to the cerebrovascular manifestations, which could be caused by alterations of the blood vessel walls or of the coagulative process induced by estrogens/progestins. The thrombogenic action of these substances could be enhanced by preexisting conditions such as protein C or protein S deficiency.
Sinibaldi
L
L
Reparto di Neurologia, G.M. Lancisi, Ospedale S. Camillo, Roma.
Gerace
C
C
Meccia
A
A
D000328:Adult; D016736:Antiphospholipid Syndrome / Q000150:complications; D002561:Cerebrovascular Disorders / Q000139:chemically induced* / Q000209:etiology / Q000503:physiopathology; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects*; D004198:Disease Susceptibility; D005260:Female; D006801:Humans; D008875:Middle Aged; D008881:Migraine Disorders / Q000150:complications; D008945:Mitral Valve Prolapse / Q000150:complications; D020151:Protein C Deficiency; D012907:Smoking
D003277:Contraceptives, Oral, Combined
Manifestazioni vascolari cerebrali in corso di assunzione di combinazioni estroprogestiniche a scopo contraccettivo. Casistica clinica.